CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03611868
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:29.791655+00:00
Published At: 2025-08-07T00:00:00+00:00
Record Updated At: 2025-08-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Unresectable or Metastatic Melanoma or Advanced Solid Tumors", "Melanoma", "Uveal Melanoma", "P53 Mutation", "MDM2 Gene Mutation", "Cutaneous Melanoma", "Mucosal Melanoma", "Malignant Peripheral Nerve Sheath Tumors (MPNST)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-07"
protocolSection.identificationModule.nctId: "NCT03611868"
protocolSection.identificationModule.officialTitle: "A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.